Aplidine (BioDeep_00000011450)
代谢物信息卡片
Dehydrodidemnin B
化学式: C57H87N7O15 (1109.6259832)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
InChI: InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
描述信息
A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans.
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
C784 - Protein Synthesis Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 (?KD=80?nM)[1]. Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research[1][2].
同义名列表
5 个代谢物同义名
Dehydrodidemnin B; Plitidepsin; Didemnin A; Aplidine; PM90001
数据库引用编号
14 个数据库交叉引用编号
- ChEBI: CHEBI:90205
- KEGG: C16862
- KEGGdrug: D11032
- PubChem: 9812534
- Metlin: METLIN71394
- DrugBank: DB04977
- ChEMBL: CHEMBL451930
- KNApSAcK: C00044529
- CAS: 137219-37-5
- PMhub: MS000025447
- MetaboLights: MTBLC90205
- PubChem: 135626062
- PDB-CCD: ZIY
- medchemexpress: HY-16050
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Martin Sachse, Raquel Tenorio, Isabel Fernández de Castro, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Dàlia Raïch-Regué, Jordi Rodon, Alejandro Losada, Pablo Avilés, Carmen Cuevas, Roger Paredes, Joaquim Segalés, Bonaventura Clotet, Júlia Vergara-Alert, Nuria Izquierdo-Useros, Cristina Risco. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
Antiviral research.
2022 04; 200(?):105270. doi:
10.1016/j.antiviral.2022.105270. [PMID: 35231500] - Jose F Varona, Pedro Landete, Jose A Lopez-Martin, Vicente Estrada, Roger Paredes, Pablo Guisado-Vasco, Lucia Fernandez de Orueta, Miguel Torralba, Jesus Fortun, Roberto Vates, Jose Barberan, Bonaventura Clotet, Julio Ancochea, Daniel Carnevali, Noemi Cabello, Lourdes Porras, Paloma Gijon, Alfonso Monereo, Daniel Abad, Sonia Zuñiga, Isabel Sola, Jordi Rodon, Julia Vergara-Alert, Nuria Izquierdo-Useros, Salvador Fudio, Maria Jose Pontes, Beatriz de Rivas, Patricia Giron de Velasco, Antonio Nieto, Javier Gomez, Pablo Aviles, Rubin Lubomirov, Alvaro Belgrano, Belen Sopesen, Kris M White, Romel Rosales, Soner Yildiz, Ann-Kathrin Reuschl, Lucy G Thorne, Clare Jolly, Greg J Towers, Lorena Zuliani-Alvarez, Mehdi Bouhaddou, Kirsten Obernier, Briana L McGovern, M Luis Rodriguez, Luis Enjuanes, Jose M Fernandez-Sousa, Nevan J Krogan, Jose M Jimeno, Adolfo Garcia-Sastre. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
Life science alliance.
2022 04; 5(4):. doi:
10.26508/lsa.202101200. [PMID: 35012962] - Heidi Ledford. Hundreds of COVID trials could provide a deluge of new drugs.
Nature.
2022 03; 603(7899):25-27. doi:
10.1038/d41586-022-00562-0. [PMID: 35233098] - Vijay Kumar Vishvakarma, Madhur Babu Singh, Pallavi Jain, Kamlesh Kumari, Prashant Singh. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
Amino acids.
2022 Feb; 54(2):205-213. doi:
10.1007/s00726-021-03098-1. [PMID: 34807314] - Mahmoud A El Hassab, Loah R Hemeda, Zainab M Elsayed, Sara T Al-Rashood, Mohammed K Abdel-Hamid Amin, Hatem A Abdel-Aziz, Wagdy M Eldehna. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
Chemistry & biodiversity.
2022 Feb; 19(2):e202100719. doi:
10.1002/cbdv.202100719. [PMID: 34813168] - P Guisado-Vasco, M M Carralón-González, J Aguareles-Gorines, E M Martí-Ballesteros, M D Sánchez-Manzano, D Carnevali-Ruiz, M García-Coca, R Barrena-Puertas, R García de Viedma, J M Luque-Pinilla, G Sotres-Fernandez, J M Fernández-Sousa, X E Luepke-Estefan, J A López-Martín, J M Jimeno. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
Journal of hematology & oncology.
2022 01; 15(1):4. doi:
10.1186/s13045-021-01220-0. [PMID: 35012608] - Muhammad Asif, Mohammad Saleem, Hafiza Sidra Yaseen, Ashwaq Hs Yehya, Malik Saadullah, Hafiz Muhammad Zubair, Chern E Oon, Pegah Moradi Khaniabadi, Syed Haroon Khalid, Ikram Ullah Khan, Mahrukh. Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.
Future microbiology.
2021 11; 16(?):1289-1301. doi:
10.2217/fmb-2021-0024. [PMID: 34689597] - J Reina. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
2021 Oct; 34(5):402-407. doi:
10.37201/req/042.2021. [PMID: 33902254] - P Guisado-Vasco, L González-Cortijo, G D'Errico, A Serrera-Alvarez, G Sotres-Fernandez, M García-Coca, J M Fernández-Sousa, X E Luepke-Estefan, J A López-Martín, J M Jimeno. Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2021 10; 32(10):1295-1297. doi:
10.1016/j.annonc.2021.07.003. [PMID: 34242743] - Miguel Angel Martinez. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
Antimicrobial agents and chemotherapy.
2021 03; 65(4):. doi:
10.1128/aac.00200-21. [PMID: 33558296] - Kris M White, Romel Rosales, Soner Yildiz, Thomas Kehrer, Lisa Miorin, Elena Moreno, Sonia Jangra, Melissa B Uccellini, Raveen Rathnasinghe, Lynda Coughlan, Carles Martinez-Romero, Jyoti Batra, Ajda Rojc, Mehdi Bouhaddou, Jacqueline M Fabius, Kirsten Obernier, Marion Dejosez, María José Guillén, Alejandro Losada, Pablo Avilés, Michael Schotsaert, Thomas Zwaka, Marco Vignuzzi, Kevan M Shokat, Nevan J Krogan, Adolfo García-Sastre. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
Science (New York, N.Y.).
2021 02; 371(6532):926-931. doi:
10.1126/science.abf4058. [PMID: 33495306] - Jason P Wong, Blossom Damania. SARS-CoV-2 dependence on host pathways.
Science (New York, N.Y.).
2021 02; 371(6532):884-885. doi:
10.1126/science.abg6837. [PMID: 33632832] - Orazio Taglialatela-Scafati. New Hopes for Drugs against COVID-19 Come from the Sea.
Marine drugs.
2021 Feb; 19(2):. doi:
10.3390/md19020104. [PMID: 33670191] - L van Andel, H Rosing, M M Tibben, L Lucas, R Lubomirov, P Avilés, A Francesch, S Fudio, A Gebretensae, M J X Hillebrand, J H M Schellens, J H Beijnen. Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin.
Cancer chemotherapy and pharmacology.
2018 09; 82(3):441-455. doi:
10.1007/s00280-018-3637-1. [PMID: 29974200] - Pau Rocas, Yolanda Fernández, Natalia García-Aranda, Laia Foradada, Pilar Calvo, Pablo Avilés, María José Guillén, Simó Schwartz, Josep Rocas, Fernando Albericio, Ibane Abasolo. Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles.
Nanomedicine : nanotechnology, biology, and medicine.
2018 02; 14(2):257-267. doi:
10.1016/j.nano.2017.10.009. [PMID: 29127040] - L van Andel, H Rosing, S Fudio, P Avilés, M M Tibben, A Gebretensae, J H M Schellens, J H Beijnen. Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.
Journal of pharmaceutical and biomedical analysis.
2017 Oct; 145(?):137-143. doi:
10.1016/j.jpba.2017.06.013. [PMID: 28662481] - L van Andel, S Fudio, H Rosing, S Munt, B Miguel-Lillo, I González, M M Tibben, N de Vries, A H M de Vries Schultink, J H M Schellens, J H Beijnen. Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.
Investigational new drugs.
2017 10; 35(5):589-598. doi:
10.1007/s10637-017-0432-5. [PMID: 28111728] - Sandrine Aspeslagh, Ahmad Awada, Arturo S Matos-Pita, Philippe Aftimos, Ratislav Bahleda, Andréa Varga, Jean-Charles Soria. Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.
Anti-cancer drugs.
2016 11; 27(10):1021-7. doi:
10.1097/cad.0000000000000409. [PMID: 27610894] - Hugo Oliveira, Julie Thevenot, Elisabeth Garanger, Emmanuel Ibarboure, Pilar Calvo, Pablo Aviles, Maria Jose Guillen, Sébastien Lecommandoux. Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.
Pharmaceutical research.
2014 Apr; 31(4):983-91. doi:
10.1007/s11095-013-1220-3. [PMID: 24287622] - Teresa Gonzalo, Giovanna Lollo, Marcos Garcia-Fuentes, Dolores Torres, Juan Correa, Ricardo Riguera, Eduardo Fernandez-Megia, Pilar Calvo, Pablo Avilés, Maria José Guillén, Maria José Alonso. A new potential nano-oncological therapy based on polyamino acid nanocapsules.
Journal of controlled release : official journal of the Controlled Release Society.
2013 Jul; 169(1-2):10-6. doi:
10.1016/j.jconrel.2013.03.037. [PMID: 23591661] - María J Muñoz-Alonso, Enrique Álvarez, María José Guillén-Navarro, Marina Pollán, Pablo Avilés, Carlos M Galmarini, Alberto Muñoz. c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.
Marine drugs.
2013 May; 11(5):1677-92. doi:
10.3390/md11051677. [PMID: 23697951] - Wen-Yan Xu, Si-Meng Zhao, Guang-Zhi Zeng, Wen-Jun He, Hui-Min Xu, Ning-Hu Tan. [Progress in the study of some important natural bioactive cyclopeptides].
Yao xue xue bao = Acta pharmaceutica Sinica.
2012 Mar; 47(3):271-9. doi:
. [PMID: 22645749] - Birgit Geoerger, Edward J Estlin, Isabelle Aerts, Pamela Kearns, Brenda Gibson, Nadège Corradini, François Doz, Pilar Lardelli, Bernardo De Miguel, Arturo Soto, Raquel Prados, Gilles Vassal. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.
European journal of cancer (Oxford, England : 1990).
2012 Feb; 48(3):289-96. doi:
10.1016/j.ejca.2011.10.036. [PMID: 22119199] - María Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, Felipe Prosper, Albert Oriol, Javier de la Rubia, Juan José Lahuerta, Ramón García-Sanz, Sonia Extremera, Sergio Szyldergemajn, Claudia Corrado, Harald Singer, Constantine S Mitsiades, Kenneth C Anderson, Joan Bladé, Jesús San Miguel. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010 Jun; 16(12):3260-9. doi:
10.1158/1078-0432.ccr-10-0469. [PMID: 20530693] - Ricardo Nalda-Molina, Belén Valenzuela, Amelia Ramon-Lopez, Bernardo Miguel-Lillo, Arturo Soto-Matos, Juan Jose Perez-Ruixo. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
Cancer chemotherapy and pharmacology.
2009 Jun; 64(1):97-108. doi:
10.1007/s00280-008-0841-4. [PMID: 18941750] - Patrick Schöffski, Vincente Guillem, Margarita Garcia, Fernando Rivera, Josep Tabernero, Martin Cullell, Jose Antonio Lopez-Martin, Patricia Pollard, Herlinde Dumez, Xavier Garcia del Muro, Luis Paz-Ares. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
Marine drugs.
2009; 7(1):57-70. doi:
10.3390/md7010057. [PMID: 19370171] - Constantine S Mitsiades, Enrique M Ocio, Atanasio Pandiella, Patricia Maiso, Consuelo Gajate, Mercedes Garayoa, David Vilanova, Juan Carlos Montero, Nicholas Mitsiades, Ciaran J McMullan, Nikhil C Munshi, Teru Hideshima, Dharminder Chauhan, Pablo Aviles, Gabriel Otero, Glynn Faircloth, M Victoria Mateos, Paul G Richardson, Faustino Mollinedo, Jesus F San-Miguel, Kenneth C Anderson. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research.
2008 Jul; 68(13):5216-25. doi:
10.1158/0008-5472.can-07-5725. [PMID: 18593922] - Miguel A Izquierdo, Angela Bowman, Margarita García, Duncan Jodrell, Marisa Martinez, Beatriz Pardo, Javier Gómez, José A López-Martin, José Jimeno, José R Germá, John F Smyth. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 May; 14(10):3105-12. doi:
10.1158/1078-0432.ccr-07-1652. [PMID: 18483378] - Esther F A Brandon, Rolf W Sparidans, Ronald D van Ooijen, Irma Meijerman, Luis Lopez Lazaro, Ignacio Manzanares, Jos H Beijnen, Jan H M Schellens. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.
Investigational new drugs.
2007 Feb; 25(1):9-19. doi:
10.1007/s10637-006-7589-7. [PMID: 16633717] - Yajaira Suárez, Laura González-Santiago, Natasha Zarich, Alberto Dávalos, Juan F Aranda, Miguel A Alonso, Miguel A Lasunción, José María Rojas, Alberto Muñoz. Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content.
Molecular pharmacology.
2006 Nov; 70(5):1654-63. doi:
10.1124/mol.106.025569. [PMID: 16928956] - J A Maroun, K Belanger, L Seymour, S Matthews, J Roach, J Dionne, D Soulieres, D Stewart, R Goel, D Charpentier, G Goss, E Tomiak, J Yau, J Jimeno, G Chiritescu. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
Annals of oncology : official journal of the European Society for Medical Oncology.
2006 Sep; 17(9):1371-8. doi:
10.1093/annonc/mdl165. [PMID: 16966366] - Susana B Bravo, María E R García-Rendueles, Rafael Seoane, Vanesa Dosil, José Cameselle-Teijeiro, Luis López-Lázaro, Juan Zalvide, Francisco Barreiro, Celia M Pombo, Clara V Alvarez. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 Nov; 11(21):7664-73. doi:
10.1158/1078-0432.ccr-05-0455. [PMID: 16278386] - Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, Nora Ady-Vago, Cecilia Guzman, Luis Lopez-Lazaro, Stéphanie Lozahic, José Jimeno, Fernando Pico, Jean Pierre Armand, José Antonio Lopez Martin, Eric Raymond. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2005 Nov; 23(31):7871-80. doi:
10.1200/jco.2005.09.357. [PMID: 16172454] - Consuelo Gajate, Faustino Mollinedo. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy.
The Journal of biological chemistry.
2005 Mar; 280(12):11641-7. doi:
10.1074/jbc.m411781200. [PMID: 15659383] - G Taraboletti, M Poli, R Dossi, L Manenti, P Borsotti, G T Faircloth, M Broggini, M D'Incalci, D Ribatti, R Giavazzi. Antiangiogenic activity of aplidine, a new agent of marine origin.
British journal of cancer.
2004 Jun; 90(12):2418-24. doi:
10.1038/sj.bjc.6601864. [PMID: 15173857] - Nicola Celli, Barbara Mariani, Francesco Di Carlo, Massimo Zucchetti, Luis Lopez-Lazaro, Maurizio D'Incalci, Domenico Rotilio. Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection.
Journal of pharmaceutical and biomedical analysis.
2004 Feb; 34(3):619-30. doi:
10.1016/s0731-7085(03)00557-0. [PMID: 15127818] - Rolf W Sparidans, Jan H M Schellens, Luis López-Lázaro, José M Jimeno, Jos H Beijnen. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.
Biomedical chromatography : BMC.
2004 Jan; 18(1):16-20. doi:
10.1002/bmc.286. [PMID: 14872544] - E Erba, M Serafini, G Gaipa, G Tognon, S Marchini, N Celli, D Rotilio, M Broggini, J Jimeno, G T Faircloth, A Biondi, M D'Incalci. Effect of Aplidin in acute lymphoblastic leukaemia cells.
British journal of cancer.
2003 Aug; 89(4):763-73. doi:
10.1038/sj.bjc.6601130. [PMID: 12915891] - Ana Cuadrado, Luis F Garcia-Fernandez, Laura Gonzalez, Yajaira Suarez, Alejandro Losada, Victoria Alcaide, Teresa Martinez, Jose Maria Fernandez-Sousa, Jose Maria Sanchez-Puelles, Alberto Munoz. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.
The Journal of biological chemistry.
2003 Jan; 278(1):241-50. doi:
10.1074/jbc.m201010200. [PMID: 12414812] - Jianming Yin, Pablo Aviles, William Lee, Carl Ly, Pablo Floriano, Manzanares Ignacio, Glynn Faircloth. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of Aplidin, a novel marine-derived antineoplastic agent, in human plasma.
Rapid communications in mass spectrometry : RCM.
2003; 17(16):1909-14. doi:
10.1002/rcm.1133. [PMID: 12876692] - N Celli, A M Gallardo, C Rossi, M Zucchetti, M D'Incalci, D Rotilio. Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications.
1999 Aug; 731(2):335-43. doi:
10.1016/s0378-4347(99)00262-5. [PMID: 10510788] - R W Sparidans, J J Kettenes-van den Bosch, O van Tellingen, B Nuyen, R E Henrar, J M Jimeno, G Faircloth, P Floriano, K L Rinehart, J H Beijnen. Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.
Journal of chromatography. B, Biomedical sciences and applications.
1999 Jun; 729(1-2):43-53. doi:
10.1016/s0378-4347(99)00118-8. [PMID: 10410926]